<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Tissue factor (TF) is emphasized as the promising target in the future targeted therapy strategy for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Recent evidence showed that TF expression is under the control of K-ras and p53 </plain></SENT>
<SENT sid="2" pm="."><plain>However, a comprehensive evaluation of TF expression, K-ras status, and p53 mutation has not been systematically analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>The aims of this study were to identify the percentages of positive TF in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients; analyze the associations of TF expression, K-ras status, and p53 mutation; and evaluate the prognostic value of TF in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Ninety-six <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> samples were tested for TF expression, p53 mutation, and K-ras status by semiquantitative immunohistochemistry, Western blotting analysis, direct sequencing, and real-time quantitative PCR </plain></SENT>
<SENT sid="5" pm="."><plain>Associations were sought with TF expression and clinical outcomes </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: TF expression was related to clinical stages, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> differentiation, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size </plain></SENT>
<SENT sid="7" pm="."><plain>The positive proportions of TF expression on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vascular endothelial cells were 70% and 53% respectively in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>The positive proportion of TF co-expression on both <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vascular endothelial cells was 40%, compared to an 83% total TF positive proportion in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="9" pm="."><plain>TF expression on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> appeared to be increased with K-ras and/or p53 mutation(s) </plain></SENT>
<SENT sid="10" pm="."><plain>Disease-free survival and overall survival were significantly reduced in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with high TF expression </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: TF may participate in both K-ras and p53 mutations involved in colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> and could be considered as a prognostic indicator for patients <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>